EUVIMEDEUVIMED entdecken
Open Access

Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus–associated oropharynx cancer early detection

Dipon Das, Shun Hirayama iD, Ling Aye, Michael E Bryan iD, Saskia Naegele iD, Brian Zhao, Vasileios Efthymiou iD, Julia Mendel, Adam S Fisch iD, Zoe Guan iD, Lea Kröller iD, Birgitta E Michels iD und 7 weitere

JNCI: Journal of the National Cancer Institute · 01.01.2026 · 118 (1) · 58-67

DOI: 10.1093/jnci/djaf249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 10.09.2025. Verfasst von Dipon Das und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, United States. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Early Detection of Cancer, Papillomavirus Infections, Circulating Tumor DNA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NCATS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early detection of HPV-associated oropharyngeal squamous cell carcinoma, the most common HPV cancer in the United States, could reduce disease-related morbidity and mortality, yet currently, there are no early detection tests. HPV circulating tumor DNA (ctDNA) is a sensitive and specific biomarker for HPV–associated oropharyngeal squamous cell carcinoma at diagnosis. It is unknown if ctDNA HPV is detectable prior to diagnosis, and thus its potential as an early detection test is also unknown.

Methods

Plasma samples from the Mass General Brigham Biobank collected 1.3-10.8 years prior to diagnosis from HPV–associated oropharyngeal squamous cell carcinoma patients (n = 28) and age- and sex-matched controls (n = 28) were blinded and run on a newly developed and validated multifeature HPV whole genome sequencing liquid biopsy assay and a validated HPV antibody assay.

Results

HPV ctDNA results were positive in 22 of 28 prediagnostic samples from HPV–associated oropharyngeal squamous cell carcinoma cases (sensitivity 79%) with a maximum lead time of 7.8 years. HPV ctDNA results were negative in all controls (0 of 28, 100% specificity). Diagnostic accuracy was highest within 4 years of cancer diagnosis and was higher than HPV Ab detection within the same timeframe (P = .004). Application of a machine-learning model trained and tested on an independent cohort of 306 cases and controls increased the sensitivity of detection to 27 of 28 cases (overall sensitivity 96%) and the maximum lead time to 10.3 years.

Conclusions

HPV ctDNA can be detected in the blood years prior to diagnosis with HPV–associated oropharyngeal squamous cell carcinoma, with high specificity, in a case-control cohort of 56 participants. HPV ctDNA detection alone, or in combination with previously identified serological biomarkers, may be a feasible approach to early detection of HPV–associated oropharyngeal squamous cell carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsEarly Detection of CancerPapillomavirus InfectionsCirculating Tumor DNADNA, ViralPapillomaviridaeCarcinoma, Squamous CellHumansMaleFemaleMiddle AgedWhole Genome SequencingAgedBiomarkers, TumorCase-Control StudiesSensitivity and SpecificitySquamous Cell Carcinoma of Head and NeckAdultHuman Papillomavirus Viruses

Substanzen

Circulating Tumor DNADNA, ViralBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, United States.
  • Massachusetts Eye and Ear, Boston, MA, United States.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
  • Department of Pathology, Massachusetts General Hospital, Boston, MA, United States.
  • Massachusetts General Hospital Biostatistics, Boston, MA, United States.
  • Division of Infections and Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany.

ORCID-Profile: Shun Hirayama, Michael E Bryan, Saskia Naegele, Vasileios Efthymiou, Adam S Fisch, Zoe Guan, Lea Kröller, Birgitta E Michels, Tim Waterboer, Jeremy D Richmon, Viktor Adalsteinsson, Matthew G Crowson, Daniel L Faden

Förderung

  • NIDCR NIH HHS
  • NCATS NIH HHS
  • NIH
  • NCI NIH HHS
  • NIDCR

Zitieren

APA

Das, D., Hirayama, S., Aye, L., Bryan, M. E., Naegele, S., Zhao, B., Efthymiou, V., Mendel, J., Fisch, A. S., Guan, Z., Kröller, L., Michels, B. E., Waterboer, T., Richmon, J. D., Adalsteinsson, V., Lawrence, M. S., Crowson, M. G., Iafrate, A. J., & Faden, D. L. (2026). Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus–associated oropharynx cancer early detection. JNCI: Journal of the National Cancer Institute, 118(1), 58-67. https://doi.org/10.1093/jnci/djaf249

Vancouver

Das D, Hirayama S, Aye L, Bryan ME, Naegele S, Zhao B, et al. Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus–associated oropharynx cancer early detection. JNCI: Journal of the National Cancer Institute. 2026;118(1):58-67. doi:10.1093/jnci/djaf249

BibTeX
@article{Das2026,
  author = {Das, Dipon and Hirayama, Shun and Aye, Ling and Bryan, Michael E and Naegele, Saskia and Zhao, Brian and Efthymiou, Vasileios and Mendel, Julia and Fisch, Adam S and Guan, Zoe and Kröller, Lea and Michels, Birgitta E and Waterboer, Tim and Richmon, Jeremy D and Adalsteinsson, Viktor and Lawrence, Michael S and Crowson, Matthew G and Iafrate, A John and Faden, Daniel L},
  title = {Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus–associated oropharynx cancer early detection},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  volume = {118},
  number = {1},
  pages = {58--67},
  doi = {10.1093/jnci/djaf249}
}
Kostenlos starten →